The patent licence terms that decide what the licence is actually worth

The grant word decides who is shut out — including the owner

Non-exclusive, sole and exclusive mean what they mean in any licence; exclusive versus non-exclusive licences covers the general comparison. Patents add one consequence the other regimes do not.

Only a patentee has a remedy by civil action for infringement. An exclusive licensee counts as one only where the licence handed over what the Federal Circuit calls all substantial rights — in which case it is an assignment however it is titled, and the owner may find it can no longer sue. Anything less and both have to be in court together.

Field of use and territory are how one patent is licensed many times

These two clauses are why a single patent can support four deals at four prices — and the only honest way to grant exclusivity to a licensee that can realistically exploit one slice of the market.

The fence has to be drawn in the right place. A field-of-use limit works because it restricts what the licensee is authorised to make and sell: sell outside the field and the authority was never there, so the sale infringes rather than exhausting the patent. A condition imposed on the buyer does not do the same work — in Impression Products v. Lexmark the Supreme Court held that any authorised sale exhausts the patent, at home and abroad alike, and that post-sale restrictions are enforceable in contract only.

The base moves more money than the rate

Both sides will spend a week on whether the rate is 3% or 4%. Then the agreement applies it to "net sales" and leaves that undefined, which moves the payment further than the rate argument did.

Two deductions need a ceiling rather than a definition, because the licensee sets them: volume discounts and sales commissions. An uncapped commission to a related distributor is the standard way a royalty quietly halves. Tax, freight, duty and documented returns are ordinary and not worth the argument. None of it means much without a reporting cadence and an audit right behind it.

Then there is the combination product: the patented part sold inside something much larger. "A percentage of the machine" is a decision to be paid for the machine, and a licensee will resist it, correctly. Apportion by relative commercial value, or fix a formula in advance. Courts treat damages the same way — the base for a multi-component product is generally the smallest saleable patent-practising unit, and the entire market value only where the patented feature drives demand.

Royalty stacking: when one product reads on several patents

A manufacturer building anything complicated is rarely licensing one patent. Each licensor sets its rate as though it were the only one, and the licensee pays all of them out of one margin. That is royalty stacking, and it stays the licensee's problem until a clause makes it shared.

The usual mechanism is an offset: where the licensee must take a third-party licence to sell lawfully, some fraction of that royalty — often half — comes off what is owed here, down to a stated floor. Three things make or break it: which third-party licences qualify, or the licensee offsets against agreements it would have signed anyway; where the floor sits, since no licensor accepts a clause reaching zero; and who decides the licence was necessary, which belongs with independent patent counsel.

An exclusive licence with no minimum is a patent nobody can use

An exclusive licensee that does nothing still holds the exclusivity: the owner cannot practise the invention, cannot license anyone else, and collects a percentage of nothing. Minimum annual royalties and dated diligence milestones are the answer, usually paired with a right to convert the licence to non-exclusive rather than terminate — a smaller ask, and easier to agree.

What makes this sharper for patents is that the asset is visibly running down. The term is 20 years from the earliest US filing date, and the licence is normally signed years into it. Maintenance fees fall due at three and a half, seven and a half and eleven and a half years after grant, each with a six-month surcharge window; miss it and the patent expires early, and the USPTO sends no reminder. Say who pays, and let the other side pay and recover if they do not.

Improvements and grant-backs decide who owns the next version

A licensee working with the technology will improve it. The grant-back clause decides what happens to those improvements, and is routinely drafted wider than either side intended.

• Define "improvement" narrowly. Anything that cannot be practised without infringing the licensed patent is fair. "Any development relating to the field" hands over the licensee's whole research programme.
• Non-exclusive beats exclusive. A non-exclusive, royalty-free grant-back lets the licensor keep using its own technology as it evolves. An exclusive grant-back takes the licensee's invention away from it, and is the version that draws antitrust attention.
• Say what happens on termination. A grant-back surviving the licence leaves the licensor holding rights in work it stopped paying for. Either it ends with the licence or it converts into something paid for.
• Handle the know-how separately. Most of what a licensee learns is not patentable. Whether it stays a trade secret is a different clause from the patent grant.

Sublicensing, "have made" rights, and who sues the infringer

Two omissions cause most of the trouble. The first is specific: a licence to "make, use and sell" without have made rights does not clearly let the licensee use a contract manufacturer, which is how nearly everything is now built. Say so if outsourced manufacture is contemplated — a narrower ask than sublicensing, and licensors rarely refuse it.

The second is enforcement. Infringement is what the exclusivity was bought to prevent, yet the licence often says nothing about who acts on it — and the owner may have no commercial reason to sue, since the infringer may be its customer elsewhere. A workable clause sets a period in which the owner must decide, gives the licensee a step-in right in the owner's name if it declines, allocates costs and divides the recovery.

Royalties stop when the patent does

That last point is a rule, not a negotiating position. In Brulotte v. Thys the Supreme Court held that a patentee cannot charge royalties for use of an invention after the patent expires, and in Kimble v. Marvel Entertainment (2015) it declined to overrule that — in a licence Marvel had entered willingly and perpetually. On expiry the invention passes to the public, and the licensor cannot charge for it.

The Court left the practical routes open. Compensation for pre-expiry use may be deferred and amortised — its own example was 10% of sales during the term, paid over forty years. A licence covering know-how as well as patents may charge a lower post-expiry rate for the non-patent rights. A portfolio licence runs to the last patent to expire. What none of them can be is the same royalty, at the same rate, continuing afterwards.

The rest of the termination clause is ordinary: what counts as material breach, the cure period, a sell-off period for finished stock, and what survives — accrued royalties, confidentiality, the fate of sublicences already granted.

Where these agreements actually go wrong

Almost never in the grant clause. The failures are quieter: a base that proved to be a different number from the one the licensor modelled, a field defined by a customer segment that stopped existing, a maintenance fee nobody was responsible for, an exclusive licensee that shelved the product for six of the patent's nine remaining years.

All four were visible on the page before signature, and all four were cheap to fix there. A patent licence is not really a permission; it is a valuation with clauses attached, and the clauses carrying the valuation are the ones that get skimmed. Offered another point on the rate or a properly defined base with an audit right behind it, take the base. Offered broad exclusivity or a narrow field with a diligence milestone, take the milestone. And find the expiry date before agreeing anything at all: that date, not the negotiation, sets the ceiling on what the deal can be worth. Which right you are licensing is a separate question, in trademark, copyright or patent; where the deal is really a sale, an IP assignment is the shorter document.